The U.S. colorectal cancer screening market is an integral part of preventive healthcare that focuses on detecting pre-cancerous polyps or growths in the colon or rectum at an early stage through various screening tests and examinations. Some of the major screening methods for colorectal cancer include Fecal Immunochemical Test (FIT), stool DNA test, flexible sigmoidoscopy, colonoscopy, and CT colonography. Rising awareness about preventive care, increasing focus on early detection and diagnosis and the availability of advanced non-invasive screening solutions are some key factors fueling the growth of the U.S. colorectal cancer screening market.
U.S. colorectal cancer screening market size was valued at US$ 5.95 Bn in 2023 and is expected to reach US$ 10.62 Bn by 2031, grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key players operating in the U.S. colorectal cancer screening market are Exact Sciences, Quest Diagnostics, Laboratory Corporation of America Holdings and Novigenix SA. Exact Sciences leads the non-invasive stool DNA screening segment with its Cologuard test.Growing U.S. Colorectal Cancer Screening Market Demand for non-invasive and pain-free screening options is expected to provide lucrative opportunities for companies developing advanced technologies like blood-based screening tests and artificial intelligence-powered imaging analysis. Cancer research organizations are also focusing on identifying ways to boost screening rates through public awareness campaigns and insurance coverage of screening tests.Technological advancements are making screening more precise and accessible through the development of non-invasive screening methods such as blood and urine tests. Companies are exploring the utility of liquid biopsy, artificial intelligence and machine learning technologies to develop more affordable and accurate multi-cancer screening panels.
Market Trends
1. Increased preference for non-invasive screening methods: Routine screening is increasingly shifting towards pain-free and non-invasive options like FIT, multi-target stool DNA testing and blood-based screening to improve compliance.2. Integration of artificial intelligence: AI and machine learning are being leveraged to develop improved imaging analytics solutions for screening colonoscopy and improve polyp detection rates.
Market Opportunities
1. Untapped growth potential in rural & low income populations: Even though screening can prevent 70% of deaths, less than 70% of eligible Americans undergo regular screening leaving scope for improvement.2. Emergence of multi-cancer screening panels: There is scope for development of sequencing-based multi-cancer screening panels that can simultaneously screen for colorectal, lung, breast and other cancers from a single blood draw to improve outcomes.
Impact of COVID-19 on the U.S. Colorectal Cancer Screening Market
The COVID-19 pandemic severely impacted the colorectal cancer screening market in the U.S. In the initial months, most screening facilities were shut down to avoid unnecessary hospital visits and focus on COVID care. This led to a massive decline in screenings being performed during this period. As per estimates, screening rates dropped by over 85-90% from pre-COVID levels during March-May 2020. With colonoscopies being an aerosol-generating procedure, it was one of the first types of procedures to be suspended or limited.As the first wave subsided, facilities gradually resumed screening activities but with strict safety protocols. Procedures were limited to only high-risk or symptomatic patients. Telehealth also became popular with many physicians reviewing colon cancer risk factors virtually and advising on screening needs. However, overall screenings were still far below pre-pandemic levels owing to ongoing safety concerns as well as economic uncertainties. This is projected to negatively impact early detection opportunities and diagnosis of colorectal cancer in the longer run.With vaccination drives in full swing and revised safety guidelines issued, the market is recovering steadily in 2021. Screening centers have expanded capacity while maintaining distancing and disinfection protocols. While it may take some more time to achieve pre-COVID screening volumes, increased awareness about resuming preventive healthcare is aiding the market recovery process. Virtual consultations continue supplementing in-person visits. Going forward, emphasis on telehealth and at-home screening kit options may help expand access and screening adherence rates in the post-COVID scenario.
Geographic ConcentrationIn
terms of value, the Northeast region accounts for the largest share of the colorectal cancer screening market in the U.S. States like New York and New Jersey have a high concentration of urban population with ready access to healthcare resources. This facilitates higher screening rates compared to the national average. The region is estimated to continue its dominance with growing health awareness and established healthcare infrastructure.Fastest Growing RegionThe South is projected to emerge as the fastest growing region for the U.S. colorectal cancer screening market in the coming years. States such as Texas, Florida and North Carolina have seen increasing acceptance of screening recommendations. Initiatives to expand Medicaid coverage for low-income groups and education programs emphasizing cancer prevention are helping to raise participation in the region. Changing patient demographics with a significant rural population also raises the focus on novel at-home testing options with virtual physician guidance.
Get More Insights On- U.S. Colorectal Cancer Screening Market
Get this Report in Japanese Language: 米国大腸がん検査市場
Get this Report in Korean Language: 미국대장암검진시장
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
